Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Communication at the request of the FSMA on the transactions with Qliniq

Communication at the request of the FSMA on the transactions with QliniqRevision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the accounting treatment of the transactions with Qliniq announced on 20 January 2023HY-088 and HY-038 considered as a non-monetary exchange under IAS 38.45 in 2023No impact on the cash flow and cash position Liège, Belgium – 14 March 2023 – 07:00AM CET – Regulated Information – Inside...

Mission Therapeutics raises £25.2 million to progress clinical candidates in the…

MTX325, a CNS penetrant which is a potential disease-modifying treatment for Parkinson's Disease, is about to enter Phase I trials; while peripherally-restricted MTX652 is currently in Phase II investigating acute kidney injury (AKI) associated with cardiac surgery. MTX325, a CNS penetrant which is a potential disease-modifying treatment for Parkinson's Disease, is about to enter Phase I trials; while peripherally-restricted MTX652 is currently in Phase II investigating acute kidney injury...

New Employee Elected Directors to the Board of Zealand Pharma A/S

Company announcement – No. 14 / 2024 New Employee Elected Directors to the Board of Zealand Pharma A/S Copenhagen, Denmark, March 13, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company's Board of Directors:Employee representatives:Frederik Beck (re-elected)Anneline Nansen (re-elected)Ludovic Otterbein (newly elected) Adam Nygaard...

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; March 13, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock…

Company Announcement COPENHAGEN, Denmark; March 13, 2024 –Genmab A/S (Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 13, 2024, the Company's Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 12,847 restricted stock units to members of the Board of Directors and employees of the Company and the Company's subsidiaries and 6,660 warrants to the...

Orexo successfully issues senior secured callable floating rate social bonds of…

Nikolaj Sørensen, President and CEO of Orexo, said: "Thanks to a strong interest, not least from international institutional investors, I am pleased to announce that we have successfully secured the refinancing of our outstanding corporate bond with a new social bond. The new bond confirms our long-term financing as we approach the launch of our new drug, OX124, on the US market and enables us to continue providing innovative treatment solutions for those who need them most." Nikolaj…

The US Pharmacy Benefit Management Market to Reach $680 Billion by 2029, Growing…

The U.S. Pharmacy Benefit Management Market Report Scope The U.S. Pharmacy Benefit Management Market Report Scope The US is the largest global pharmacy benefit management market revenue contributor. The demand for the pharmacy benefit management market is rising due to multiple factors, including the rising baby boomers, the rising aging population, the increase in healthcare expenditure, the growing prevalence of heart diseases and nerve disorders, and the growing awareness among the...

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63…

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care. ECMO machines play a pivotal role in sustaining life during severe heart and lung dysfunction, allowing these vital organs to recover by oxygenating blood outside the body and removing carbon dioxide. The increasing incidence of cardiovascular and respiratory…

Passing of Genmab A/S' Annual General Meeting

Company Announcement At Genmab A/S' Annual General Meeting held today March 13, 2024, the Annual Report for 2023 was approvedDischarge was given to the Board of Directors and the Executive Management and the year's profit was carried forwardThe 2023 Compensation Report was approvedSix members of the Board of Directors were re-electedDeloitte was elected as the new auditor of the CompanyThe proposal from the Board of Directors on the Board of Directors' remuneration for...

Medical Grade Skincare Market Projected to Reach $168.06 billion by 2030 -…

In dermatological advancements, medical-grade skincare products stand out for their meticulously formulated, potent compositions, addressing diverse skin concerns. These superior-quality products, enriched with higher concentrations of active ingredients such as retinoids, alpha hydroxy acids (AHAs), beta hydroxy acids (BHAs), antioxidants, and peptides, are typically dispensed through licensed healthcare professionals, including dermatologists and physicians. Their efficacy is backed by…

Electroceuticals Market / Bioelectric Medicine Market Worth $33.6 billion |…

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222053956 Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222053956 Browse in-depth TOC on "Electroceuticals Market / Bioelectric Medicine Market" 457 - Tables 46 - Figures 400 - Pages Electroceuticals Market / Bioelectric Medicine Market Scope: The cardiac pacemakers & implantable cardioverter defibrillators segment...

Urology Supplements Market Worth $3.29 Bn by 2031 - Exclusive Report by…

According to the latest research by InsightAce Analytic, the Global Urology Supplements Market is valued at US$1.74 Bn in 2023, and it is expected to reach US$ 3.29 Bn by 2031, with a CAGR of 8.43% during the forecast period of 2024-2031. According to the latest research by InsightAce Analytic, theGlobal Urology Supplements Marketis valued atUS$1.74 Bn in 2023, and it is expected to reach US$ 3.29 Bnby 2031,with aCAGR of 8.43%during theforecast period of 2024-2031...

Cinnamon Bark Oil Market to Reach US$ 146.9 Million by 2031, Rising at a CAGR of…

The Cinnamon Bark Oil Market is driven by the increasing demand for natural ingredients in various industries such as food and beverages, cosmetics, and pharmaceuticals. Cinnamon bark oil is known for its antimicrobial, antioxidant, and anti-inflammatory properties, which is driving its popularity among consumers. Additionally, the rising awareness about the health benefits of cinnamon bark oil, such as its ability to improve digestion and boost immunity, is further fueling market growth. The...

Aromatherapy Market Booming to $13 Billion by 2034 as Mental Health Issues Drive…

Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-1080 Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-1080 Propagation of alternative medicine as a remedy for various disorders is helping the demand to increase in thearomatherapy market. Essential oils are a prominent type of aromatherapy and their popularity is...

Pulsenmore is expanding the application of its home ultrasound solution for…

Traditional antenatal testing, like the biophysical profile (BPP), typically conducted in clinical settings, involves assessing fetal parameters such as movement, tone, breathing, and fluid levels using ultrasound, and sometimes combined with a non-stress test. Traditional antenatal testing, like the biophysical profile (BPP), typically conducted in clinical settings, involves assessing fetal parameters such as movement, tone, breathing, and fluid levels using ultrasound, and sometimes…

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland

COPENHAGEN, Denmark, March 13, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS ®(MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older.The approval represents the first national marketing authorization issued to Bavarian Nordic since 2019 and was facilitated by the Swiss authorities in response to the 2022 global mpox outbreak...

Annual General Meeting 2024 – GN Store Nord A/S

/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 19, 2024, as set out below. The report by the Board of Directors was noted by the general meeting. The Annual Report 2023 and the proposal on distribution of annual profits, including no distribution of dividends, were approved, and discharge was granted to the Board of Directors and the Executive Management.The general meeting approved the remuneration to the Board...

AB Science: New research shows that masitinib limits neuronal damage in a model…

PRESS RELEASENEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASETHIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS Paris, March 13, 2024, 12.45pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced the publication of new preclinical results for masitinib in neurodegenerative diseases (NDD). Findings have been...

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and…

ZYNLONTA ®(loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settingsFocused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platformFY 2023 operating expenses decreased 21% 1year-over-yeardue to portfolio prioritization and...

Communication at the request of the FSMA on the transactions with Qliniq

Mission Therapeutics raises £25.2 million to progress clinical candidates in the…

New Employee Elected Directors to the Board of Zealand Pharma A/S

Transactions with shares and linked securities in Genmab A/S made by managerial…

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock…

Orexo successfully issues senior secured callable floating rate social bonds of…

Supply & Demand Chain Executive Honors TraceLink CEO Shabbir Dahod with…

Inventiva to present the results of LEGEND Phase IIa combination trial with…

Personalized Gifting Market - Europe and the US Set to Battle for Dominance…

Prostate Cancer - Market Outlook, Epidemiology, Competitive Landscape, and…

Oxurion Receives Transparency Notification from Atlas Special Opportunities…

The US Pharmacy Benefit Management Market to Reach $680 Billion by 2029, Growing…

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63…

Passing of Genmab A/S' Annual General Meeting

Medical Grade Skincare Market Projected to Reach $168.06 billion by 2030 -…

Electroceuticals Market / Bioelectric Medicine Market Worth $33.6 billion |…

Urology Supplements Market Worth $3.29 Bn by 2031 - Exclusive Report by…

Cinnamon Bark Oil Market to Reach US$ 146.9 Million by 2031, Rising at a CAGR of…

Aromatherapy Market Booming to $13 Billion by 2034 as Mental Health Issues Drive…

Pulsenmore is expanding the application of its home ultrasound solution for…

Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Annual General Meeting 2024 – GN Store Nord A/S

AB Science: New research shows that masitinib limits neuronal damage in a model…

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and…